共 152 条
[1]
Bultron G(2010)The risk of Parkinson's disease in type 1 Gaucher disease J Inherit Metab Dis 33 167-173
[2]
Kacena K(2013)Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: results from a randomized, double-blind, multinational, Phase 3 study Am J Hematol 88 166-171
[3]
Pearson D(2015)Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: long-term data from phase III clinical trials Am J Hematol 90 584-591
[4]
Boxer M(2009)Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis Br J Haematol 147 561-570
[5]
Yang R(2016)Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naive to enzyme replacement therapy or previously treated with imiglucerase Mol Genet Metab 117 164-171
[6]
Sathe S(2003)Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3 J Pediatr 143 273-276
[7]
Gonzalez DE(2021)Investigating health-related quality of life in rare diseases: a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type 2) Orphanet J Rare Dis 16 217-1656
[8]
Turkia HB(1987)The measurement of performance in childhood cancer patients Cancer 60 1651-588
[9]
Lukina EA(2007)Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease Clin Genet 71 576-37
[10]
Kisinovsky I(2013)Quality of life of brazilian patients with Gaucher disease and fabry disease JIMD Rep 7 31-386